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Abstract
Background: The molecular mechanisms governing the formation of the embryonic vascular
system remain poorly understood. Here, we show that Disabled-2 (Dab2), a cytosolic adaptor
protein, has a pivotal role in the blood vessel formation in Xenopus early embryogenesis.
Results:  Xenopus Disabled-2 (XDab2) is spatially localized to the blood vessels including the
intersomitic veins (ISV) in early embryos. Both antisense morpholino oligonucleotide (MO)-
mediated knockdown and overexpression of XDab2 inhibit the formation of ISV, which arise from
angiogenesis. In addition, we found that activin-like signaling is essential for this angiogenic event.
Functional assays in Xenopus animal caps reveal that activin-like signals induce VEGF expression and
this induction can be inhibited by XDab2 depletion. However, XDab2 MO has no effects on the
induction of other target genes by activin-like signals. Furthermore, we show that the disruption of
the sprouting ISV in XDab2-depleted embryos can be rescued by coexpression of VEGF.
Conclusion: Taking together, we suggest that XDab2 regulates the embryonic angiogenesis by
mediating the VEGF induction by activin-like signaling in Xenopus early development.
Background
During embryogenesis, the formation of blood vessels is
accomplished by two distinct processes called vasculogen-
esis and angiogenesis. In the former process, angioblasts
derived from the lateral plate mesoderm migrate and dif-
ferentiate into endothelial cells, thereby forming endothe-
lial tube and primary vessels. And then the latter process
involves the sprouting of new vessels from these primary
vessels and their proper remodeling [1-3].
VEGF (vascular endothelial growth factor) is well known
to have critical roles in the formation of blood vessels
[4,5]. It affects not only the differentiation of angioblasts
and the formation of endothelial tube during vasculogen-
esis but also the degradation of extracellular matrix and
the proliferation and migration of endothelial cells during
angiogenesis [6-12]. Some evidence shows that HIF-1
(hypoxia-inducible factor 1), a critical factor expressed in
hypoxic condition, is involved in the induction of VEGF
[13-17]. In addition, recent studies using some cultured
cells have showed that TGFβ could induce VEGF gene [18-
23]. However, little is known regarding the molecular
mechanism by which VEGF induction is regulated in vivo,
despite its pivotal effects on blood vessel formation.
During Xenopus development, flk-1, a VEGF receptor, is
expressed in endothelial precursor cells which will form
the major blood vessels including the posterior cardinal
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veins (PCV), the dorsal aorta (DA) and the vitelline veins,
and VEGF is localized in tissues, such as hypochord 3 and
somites, adjacent to the flk-1 expressing endothelial pre-
cursors [24]. After establishment of the primary vascula-
tures, flk-1 expression is also observed in the intersomitic
veins (ISV) formed by angiogenesis. These results suggest
a role for VEGF/flk-1 signaling in both vasculogenesis and
angiogenesis in Xenopus early embryos. Supporting this
possibility, ectopic expression of VEGF  by injection of
either plasmid DNA or synthetic mRNA altered the archi-
tecture of developing vasculature [24]. In addition,
ectopic VEGF could act as a chemoattractant for angiob-
lasts, suggesting that localized sources of VEGF play a role
in patterning the embryonic vessels [25].
Disabled (Dab) was first known as a factor to affect the
neuronal development of Drosophila [26]. And then Disa-
bled-2 (Dab2), one of its mammalian isoforms, which
contains an N-terminal PTB domain and a C-terminal
PRD [27], was identified as a cytosolic adaptor regulating
endocytosis [28]. Dab2-null mice reveal that it has signif-
icant roles in endodermal cell positioning and structure
formation of the extra-embryonic visceral endoderm dur-
ing early embryogenesis, and in adult kidney function
[29,30]. It was also suggested that Dab2 could be a tumor
suppressor since its expression level, which is maintained
in normal ovarian cells, is remarkably decreased in ovar-
ian carcinoma cells [31]. Moreover, Dab2 acts as an adap-
tor to link TGFβ receptor to Smad2 or Smad3 resulting in
the promotion of TGFβ signaling pathway [32], whereas it
regulates negatively the canonical Wnt/β-catenin signal-
ing pathway [33].
In our initial attempt to address the function of Dab2 in
Xenopus early development, we unexpectedly found that
its expression is specifically restricted to blood vessels.
Inhibition of Dab2 function or activin-like signaling in
Xenopus  early embryos disrupted the intersomitic veins
arising from angiogenesis. Interestingly, its knockdown
specifically inhibited the induction of VEGF gene with no
effects on that of other target genes by activin-like signals.
We also found that defects in intersomitic veins caused by
Dab2 depletion could be rescued by coexpression of
VEGF. Therefore, we suggest in this study that Dab2 plays
pivotal roles in embryonic angiogenesis by acting as a
mediator of activin-like signaling pathway for VEGF
induction.
Results
Xenopus Dab2 is expressed in embryonic vasculature
To investigate the function of Dab2 in Xenopus  early
embryos, we first cloned a Xenopus orthologue of Disa-
bled-2 (Dab2) by using PCR-based method and sequence
information in EST database. Xenopus Disabled-2 (XDab2)
cDNA consists of 1668 nucleotides which encode a pro-
tein of 555 amino acids (GenBank accession no.
DQ367065, Fig. 1A). The predicted amino acid sequence
of our clone is more similar to Dab2 orthologues of other
vertebrates than Dab1 (Tab.1). Like other orthologues, it
contains both N-terminal phosphotyrosine binding (PTB)
domain (or phosphotyrosine interacting domain; PID)
and C-terminal proline-rich domain (PRD). PTB and PRD
domains show over 87% and 40% identity, respectively,
across species. Furthermore, sequence alignment reveals
that XDab2 is most similar to the short splicing isoforms
(mouse, p67; rat, p59) of mammalian Dab2 (Table 1),
which lack the motifs required for Dab2 to act as an adap-
tor for endocytosis in vivo.
We next examined the spatial and temporal expression
patterns of XDab2 (Fig. 1B–G). RT-PCR analysis showed
both its maternal and zygotic transcriptions throughout
early development (Fig. 1B). Particularly, it increased
gradually after the late neurula stages. Spatially, it was
weakly expressed in the animal hemisphere at the cleav-
age stages (Fig. 1C and 1D) and around the anterior bor-
der of neural plate and somitic region at the neurula (Fig.
1E and 1F) and tailbud stages (Fig. 1G and 1H). At the late
tailbud stages, XDab2 is found in vitelline vein networks
(Fig. 1I). As development proceeds, it appeared in the
pronephric sinus and posterior cardinal veins (Fig. 1J) and
concomitantly disappeared in the somites. During the
tadpole stages, its specific and strong transcriptions were
observed in the vasculatures including vascular vitelline
vein networks (VVN), anterior cardinal veins (ACV), com-
mon cardinal veins (CCV), pronephric sinus (PS), poste-
rior cardinal veins (PCV) and intersomitic veins (ISV)
(Fig. 1K).
Overexpression of XDab2 affects the formation of 
intersomitic veins
Based on its spatial localization to vascular structures, we
focused on the function of XDab2 in the formation of
blood vessels during Xenopus early development. Thus, we
first examined the effects of gain-of-XDab2 function on
the formation of vascular structures in early embryos. To
this end, we overexpressed XDab2 mRNA in one blast-
omere of 2-cell stage embryos and then observed its effects
on vascular formation by hybridizing against Xmsr  or
EphB4, endothelial specific markers of Xenopus embryo
[34,35]. As shown in Fig. 2, the formation of intersomitic
veins (ISV) was disrupted on the injected side of XDab2-
overexpressed embryos (Fig. 2A and 2B, arrowheads) in a
dose-dependent manner (Fig. 2C). However, injection of
β-gal RNA had no effects on the growth of ISV in negative
control embryos (Fig. 2A, arrows). Since XDab2 is a short
splicing form, we also tested whether the long splicing
form of Dab2 could affect ISV formation. Interestingly,
overexpression of long splicing form of human Dab2
(p96) or mouse Dab2 (p96) in Xenopus  embryos alsoBMC Developmental Biology 2006, 6:63 http://www.biomedcentral.com/1471-213X/6/63
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impeded ISV formation (Additional file 1 and 3). The
intersomitic veins are formed by sprouting angiogenesis
[36]. In Xenopus, they appear from stage 30 on by sprout-
ing from the posterior cardinal vein and growing dorsally
into the spaces that separate individual somites [37].
Together, these results suggest that both of splicing forms
of Dab2 may have conserved functions in ISV formation
or angiogenesis.
XDab2 knockdown leads to defects in blood vessel 
formation
In order to address whether XDab2 is indispensable for
ISV formation, we next carried out the loss-of-function
analysis by using antisense morpholino oligonucleotides
(MO) capable of depleting XDab2 protein [38]. We
designed two morpholino oligonucleotides (MO1 and
MO2) which target different regions of XDab2 gene to dis-
Comparison of Dab2 homologue sequences and spatiotemporal expression pattern of Xenopus Dab2 Figure 1
Comparison of Dab2 homologue sequences and spatiotemporal expression pattern of Xenopus Dab2. (A) Align-
ment of Xenopus, human, rat, mouse and zebrafish Dab2 sequences. They contain the conserved N-terminal PTB and C-termi-
nal PRD domains. The identities between the domains are shown as percentages. (B-K) The spatial and temporal expression 
patterns of XDab2. (B) RT-PCR analysis showing the temporal expression pattern of XDab2 in Xenopus early development. 
Stages are indicated above the lanes. ODC serves as a loading control. (C) Animal view of a one-cell stage embryo. (D) Lateral 
view of a cleavage stage embryo. (E) Anterior view of a neurula stage embryo with dorsal at top. (F) A neurulae viewed dorsally 
with anterior at bottom. (G) Lateral view of a tailbud stage embryo showing XDab2 expressed in presomitic region. (H) Dorsal 
view of a tailbud stage embryo with anterior at left. (I and J) Lateral view of late tailbud stage embryos. (K) A tadpole stage 
embryo in which XDab2 is expressed in the pronephric sinus (PS), vascular vitelline networks (VVN), anterior cardinal veins 
(ACV), common cardinal veins (CCV), posterior cardinal veins (PCV) and intersomitic veins (ISV).
XDab2
ODC
B
Egg
St.8
St.11
St.13
St.19
St.23
St.32
St.42
-RT
A
ISV
PCV PS
ACV
CCV VVN
C D J I
E F
K
G HBMC Developmental Biology 2006, 6:63 http://www.biomedcentral.com/1471-213X/6/63
Page 4 of 14
(page number not for citation purposes)
rupt the translation of XDab2 mRNA (Additional file 2.
Figure S2A).
To confirm the efficacy and targeting specificity of XDab2
MOs, we first coinjected the MOs with C-terminally Myc-
tagged XDab2 RNAs with or without MO targeting sites in
four-cell stage embryos, cultured until stage 12.5, and per-
formed the Western blot analysis with the anti-Myc anti-
body (Additional file 2. Figure S2B). Coinjection of either
MO1 or MO2 inhibited effectively the production of
XDab2-Myc protein from RNAs that contain 5' untrans-
lated region (UTR) encoding MO targeting sites but not
that from RNAs devoid of 5' UTR. Control MO (Co MO)
had no effects on the production of XDab2-Myc, regard-
less of whether RNAs include MO targeting sites or not.
Overall, these indicate the ability of XDab2 MO to block
specifically the production of Xenopus Dab2 protein.
We next examined the effects of XDab2 depletion on ISV
formation. One blastomere of two-cell stage embryo was
injected with XDab2 MO (mixture of the same amounts of
MO1 and MO2 will be designated XDab2 MO hereafter)
or Co MO, and the sprouting ISV was observed by hybrid-
izing against endothelial markers at the tadpole stages. As
shown in Fig. 3, the sprouting intersomitic veins were
absent on the injected side (Fig. 3B and 3C, arrowheads)
of XDab2 MO-injected embryos as visualized by Xmsr or
EphB4 endothelial markers. And these angiogenic defects
could be rescued by coexpression of XDab2, human Dab2
(p96) or mouse Dab2 (p67) mRNA, which cannot bind to
MO and is resistant to translation inhibition (Fig. 3D, 3E
and Additional file 3). This indicates the specific effects of
XDab2 MO on the formation of ISV and the functional
conservation of splicing forms of Dab2 across species.
However, Co MO had no effects on the sprouting ISV (Fig.
3A). Moreover, we performed microangiography to exam-
ine the blood circulation in XDab2-depleted embryos at
the later stages (Fig. 3F and 3G) [39]. In this experiment,
we found that MO-mediated knockdown of XDab2 could
lead to abnormality in blood supply, causing the leak (Fig.
3F, arrowhead) or absence (Fig. 3F, asterisks) of intersom-
itic veins while Co MO-injected embryos show normal
circulation (Fig. 3G). This indicates that consistent with
the angiogenic defects shown by endothelial markers'
expression at the earlier stages, XDab2 depletion ulti-
mately can disrupt blood circulation at the advanced
stages. Furthermore, we also investigated the effects of
XDab2 depletion on the vasculogenic processes including
the formation of posterior cardinal vein (PCV) and vitell-
ine vein networks (VVN) (Fig. 3J and 3K). PCV (Fig. 3K,
arrows) and VVN (Fig. 3K, arrowheads) in a series of
embryo sections were absent or decreased on the XDab2
MO-injected side. Taken together, these results indicate
that Dab2 is essential for vasculogenesis as well as angio-
genesis during Xenopus early development.
Disturbance of activin-like signaling leads to defects in ISV 
formation
TGFβ is known to induce the expression of VEGF, a key
molecule in angiogenesis in some cultured cells [20-23].
Thus, we next investigated whether TGFβ or similar sign-
aling pathways would be involved in embryonic angio-
genesis during Xenopus  development. For this purpose,
constitutively active activin receptor (CA hALK4) [40],
dominant negative activin receptor (DN hALK4) [41],
dominant negative Smad2 (DN Smad2) or dominant neg-
ative Smad3 (DN Smad3) [42] DNA was injected into one
blastomere of two-cell stage embryos and then their
Table 1: Homology comparison among Dab2 and Dabl from different species
Identity Percentage
Dab2 Dab1
Xenopus Zebrafish Mouse p96 Mouse p67 Ratp82 Rat p59 Human Zebrafish Mouse Rat Human
Dab2 Xenopus 100 47.6 41.6 57.6 41.4 57.3 44.5 35 35.5 35.5 35.9
Zebrafish - 100 33.5 45.2 33.9 45.5 34.2 33.3 33.4 33.3 32.9
Mouse p96 - - 100 71.5 94.4 67.4 82.8 27.5 31.2 31.3 31.6
Mouse p67 - - - 100 67.4 94.2 57.6 32. 6 37 37.6 37
Ratp82 - - - - 100 71.6 82.7 26.9 30.8 31.4 31.1
Ratp59 - - - - - 100 58.1 32.5 36.9 37.4 36
Human - - - - - - 100 28.9 31.5 32.2 32.1
Dab1 Zebrafish - - - - - - - 100 62.9 63.4 63.9
Mouse - - - - - - - - 100 98.9 96.6
Rat - - - - - - - - - 100 96.8
Human - - - - - - - - - - 100
XDab2 amino acid sequence is more homologous to other vertebrate Dab2 than to Dab1 and is most similar to short splicing isoforms of 
mammalian Dab2 (mouse p67, 57.6% identity; rat p59, 57.3% identity) as shown here.BMC Developmental Biology 2006, 6:63 http://www.biomedcentral.com/1471-213X/6/63
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effects on ISV formation was examined by in situ hybridi-
zation analysis using Xmsr probe (Fig. 4). We excluded
embryos exhibiting abnormal morphology which is prob-
ably due to the effect of other functions of activin-like sig-
naling pathway during embryogenesis but analyzed
normal-looking embryos at early tadpole stages. In these
analyses, injection of CA hALK4  or DN hALK4  caused
defects in ISV formation on the injected side of embryos
to a similar degree (Fig. 4B and 4C). In addition, func-
tional inhibition of Smad3, a downstream effector of
TGFβ signaling, by expression of DN Smad3 disrupted the
sprouting of ISV (Fig. 4D). DN Smad2 had also inhibitory
effects on ISV formation, but to a lesser extent than DN
Smad3. Overall, these data suggest that activin-like signal-
ing may affect on normal embryonic angiogenesis during
Xenopus early development.
Activin-like signaling regulates ISV formation through 
XDab2-mediated VEGF induction
Our results revealed that XDab2 and activin-like signal are
essential for ISV formation in developing early embryos.
Since Dab2 acts as an adaptor to mediate TGFβ signaling
pathway [32], we next examined whether XDab2 might
function downstream of activin-like signaling pathway to
mediate VEGF gene expression for the regulation of blood
vessel formation. To this end, we first performed RT-PCR
analysis to test whether XDab2 mediates the induction of
VEGF by activin-like signal (Fig. 5A). Functional analysis
in Xenopus animal caps showed that injection of constitu-
tively active activin receptor (CA hALK4) could induce
VEGF  gene, and this induction could be interfered by
coexpression of XDab2 MO. Co MO, however, did not
affect the expression of VEGF. We also carried out this
Overexpression of XDab2 disrupts the sprouting of ISV Figure 2
Overexpression of XDab2 disrupts the sprouting of ISV. (A and B) Injection of XDab2 RNA inhibits the formation of 
the sprouting ISV on the injected side of the embryo, with that on the uninjected side being normal. The same amount of con-
trol nuclear β-galactosidase (β-gal) RNA shows no effects on the ISV sprouts. One blastomere of two-cell stage embryos was 
injected with β-gal RNA as a lineage tracer with or without XDab2 RNA. Embryos were fixed at stage 34, stained for β-gal and 
then hybridized against Xmsr (A) or EphB4 (B). Arrows and arrowheads indicate the normal and disrupted ISV on the injected 
side of the embryo, respectively. Rectangular areas in the upper panels are enlarged in the lower panels. (C) The table showing 
the results from the gain-of-function analysis of XDab2. Overexpression of XDab2 causes the angiogenic defects in a dose-
dependent manner.
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analysis using Xnr1 (Xenopus nodal-related 1), a ligand of
Nodal signaling, with the same result (data not shown).
Together, these results suggest that XDab2 may mediate
the induction of VEGF by activin-like signaling. Further-
more, we examined whether XDab2 depletion also inhibit
the expression of endogenous VEGF in whole embryos.
For this purpose, we injected Co MO or XDab2 MO into
one blastomere of two-cell stage embryos and then per-
formed in situ hybridization analysis using VEGF probe
[24] at the embryonic stages just prior to the formation of
blood vessels including PCV and ISV (Fig. 5B and 5C).
VEGF  gene expression was decreased markedly on the
injected side of XDab2 MO-injected embryos (Fig. 5C)
whereas it was unchanged in the Co MO-injected embryos
(Fig. 5B). Since overexpression of Dab2  or DN hALK4
could inhibit ISV formation as shown above, we also
examined their effects on the expression of endogenous
VEGF. As shown in Fig. 5D and 5E, injection of XDab2 or
hDab2 did not induce significant changes in VEGF expres-
sion, though a small percentage of injected embryos
exhibited its increased pattern (data not shown). In con-
trast, DN hALK4-mediated inhibition of activin-like sign-
aling suppressed VEGF expression (Fig. 5F). Overall, these
data suggest that Dab2-mediated activin-like signaling is
essential for VEGF  expression in vivo during Xenopus
development.
As VEGF has a key role in angiogenesis, we next asked
whether the XDab2-mediated induction of VEGF is rele-
vant to ISV formation in Xenopus early embryos. To test
this, we examined whether the angiogenic defects caused
by XDab2 depletion could be rescued by coexpression of
VEGF (Fig. 5H–J). In this experiment, injection of XDab2
MO inhibited the formation of intersomitic veins as
described above (Fig. 5I, arrowheads), and this inhibition
could be rescued by coinjection of Xenopus VEGF mRNA
[24,25] (Fig. 5J). These data indicate that the XDab2-
mediated induction of VEGF may regulate the growth of
intersomitic veins in early embryos.
Activin-like signals have a variety of roles during the pat-
terning of Xenopus early embryos, and many other target
genes as well as VEGF are induced by these signals in ani-
mal caps. We thus tested whether XDab2 also mediates
the induction of other target genes by activin-like signals
(Fig. 6). Intriguingly, our results showed that XDab2 MO
inhibited the induction of late mesodermal markers
including VEGF and muscle actin (MA), but not that of
endodermal markers including endodermin (Edd) or
Sox17 genes by expression of CA hALK4 in animal caps
(Fig. 6A). In addition, XDab2 depletion did not affect the
induction of earlier mesodermal markers such as Xbra,
Chordin and Mix2 by activin-like signals (Fig. 6B). Consist-
ently, XDab2 could enhance the activity of activin ligand
in the induction of VEGF gene only, but not in that of
other target genes (Fig. 6C). These results suggest that
XDab2 may function as a specific adaptor to induce VEGF
downstream of activin-like signaling pathway.
Discussion
In this study, we have demonstrated that activin-like sign-
aling pathway is implicated in angiogenesis in Xenopus
early embryos and Dab2 acts as a specific mediator for this
process. First, Xenopus Dab2 is specifically expressed in
vasculatures of early embryos including intersomitic veins
(ISV). Second, overexpression and depletion of XDab2
interferes with the sprouting of ISV. In addition, the up-
and down-regulation of activin-like signaling by expres-
sion of CA hALK4, DN hALK4, DN Smad2 or DN Smad3
affects the formation of ISV. Finally, XDab2 is required for
the induction by activin-like signals of VEGF, a critical
angiogenic factor, with no effects on that of other target
genes. Together, these results suggest the possible signal-
ing cascade that regulates the early vascular development
in vertebrates.
Angiogenic defects caused by the gain- and loss-of-
function of XDab2
Our results show that both overexpression and knock-
down of XDab2 can cause the disappearance of the inter-
somitic veins (Figs. 2 and 3). This angiogenic defect by
XDab2 depletion may be due to the loss of XDab2-medi-
ated VEGF expression. Consistent with this, analysis of
heterozygous  VEGF  mutant embryos, which are less
affected than those homozygous for this mutation,
revealed a strong decrease in ISV sprouts [7]. Moreover,
even loss of a single VEGF  allele results in embryonic
lethality at E11.5, indicating a strict dose-dependent regu-
lation of embryonic blood vessel development by VEGF
[7,10,43]. Then, the next question to address is how the
absence of the sprouting ISV could be caused by XDab2
overexpression, although several molecules involved in
embryonic angiogenesis show similar phenotypes in the
gain-and loss-of-function analysis [37,44]. Two possibili-
ties could account for this finding. First, VEGF increased
by XDab2 may interfere with the formation of angiogenic
vessels. In quail embryogenesis, the intersomitic arteries
in the VEGF-injected halves were either missing or
stunted, whereas in the uninjected halves, the intersomitic
and vertebral vessel development was normal [45]. This
indicates that ectopic expression of VEGF could induce
angiogenic defects. In addition, loss of ALK1, which is a
member of TGFβ type I receptors and activates Smad1/5/
8 effectors, leads to up-regulation of angiogenic factors
such as VEGF and Ang-2 (angiopoietin-2). Nevertheless,
ALK1 knockout mice exhibited defective angiogenesis and
vascular smooth muscle cell development, although
endothelial differentiation and vasculogenesis appear
normal [46]. Second, it is possible that up-regulation of
activin-like signaling by overexpression of XDab2  mayBMC Developmental Biology 2006, 6:63 http://www.biomedcentral.com/1471-213X/6/63
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induce anti-angiogenic factors as well as VEGF. TGFβ can
both stimulate and inhibit proliferation of endothelial
cells. Low doses of TGFβ stimulate proliferation and
migration of endothelial cells, while high doses of TGFβ
inhibit these responses [47]. Recent evidence has shown
that TGFβ signaling could induce both the angiogenic
molecule, VEGF, and the anti-angiogenic molecules such
as thrombospondin-1 (TSP-1), known as a major antian-
giogenic factor, and soluble Flt-1 (sFlt-1), which is a solu-
ble receptor and antagonist of VEGF [48]. In light of this,
it is tempting to speculate that XDab2-promoted activin-
like signaling may stimulate the expression of anti-ang-
XDab2 is required for the formation of ISV sprouts Figure 3
XDab2 is required for the formation of ISV sprouts. (A) Control embryos injected with Co MO (30 ng) show no 
defects in the sprouting ISV. (B-E) XDab2 knockdown impedes the formation of ISV and this inhibitory effect can be rescued by 
coexpression of Xenopus Dab2 (D) or human Dab2 (E) RNA, which is resistant to the translational inhibition of MO. One blas-
tomere of two-cell stage embryos was injected with XDab2 MO (30 ng) alone or with XDab2 RNA (250 pg) or hDab2 RNA 
(250 pg), and then embryos fixed at stage 34 were insituhybridized against Xmsr (B, D and E) or EphB4 (C). Arrows and arrow-
heads represent the normal and disrupted ISV, respectively. (F and G) Microangiography showing that XDab2 depletion causes 
abnormality in blood circulation in stage 42 embryos (F: 47%, n = 17), while Co MO-injected embryos reveal the normal circu-
lation (G: 0%, n = 8). Arrowhead and asterisks represent the leaky vessels and the absence of ISV, respectively. DLAV, the dor-
sal longitudinal anastomosing vessel; DA, the dorsal aorta; PCV, the posterior cardinal veins; ISV, the intersomitic veins. (H and 
I) The graph and table showing the results from the loss-of-function analysis of XDab2. (J and K) Loss-of-function of XDab2 
interferes with vasculogenesis. (J) The illustration of transverse section analysis. Roman numerals (I – IV) indicate the positions 
of embryo sections shown in panel (K). (K) A series of embryo sections show the absence or decrease of the endothelial 
marker, Xmsr in PCV (arrows) and VVN (arrowheads) on the XDab2 MO-injected side, which is indicated by the β-galactosi-
dase staining. The XDab2 knockdown embryos (n = 12) with the angiogenic defects were analyzed and all of them showed 
these phenotypes.
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iogenic factors in Xenopus early embryos, and then these
factors could inhibit the function of VEGF. The role of
anti-angiogenic factors including TSP-1 and sFlt-1 and
their relationship with activin-like signaling in angiogen-
esis during Xenopus early development remain to be inves-
tigated.
Dab2-mediated activin-like signaling in angiogenesis
Our gain- and loss-of-function analysis of activin-like sig-
naling suggests its possible role in angiogenesis at later
stages of Xenopus early development. Consistently, deple-
tion of TGFβ and its receptors has demonstrated the criti-
cal role of TGFβ signaling in vascular development.
TGFβ1-deficient mice die in utero due to vascular defects
[49] and loss of TGFβ type I or type II receptor in mice
results in embryonic lethality at around E10.5 due to
defects in vascular development of the yolk sac [50,51]. In
addition, several reports have shown that TGFβ signaling
induces VEGF gene expression in cultured cells [18-23].
However, the molecular mechanisms underlying the reg-
ulation of VEGF gene expression in whole organisms are
poorly understood.
Dab2 is known to function as a component of TGFβ sign-
aling by linking TGFβ receptors and Smad proteins in cul-
tured cells [32]. This suggests the possibility that XDab2
regulates embryonic angiogenesis through activin-like sig-
naling pathway. Supporting this hypothesis, unlike wild-
type XDab2, its mutant devoid of PTB domain, which
mediates its interaction with TGFβ receptors and Smad2/
3, could not inhibit the sprouting of ISV when over-
expressed in early embryos (data not shown). Moreover,
XDab2 is not only required for but also capable of aug-
menting the ability of activin signal to induce VEGF gene
(Fig. 6C). These results indicate that XDab2 lies in the
activin-like signaling cascade for the regulation of the ang-
iogenic events. Interestingly, our results reveal that deple-
tion of XDab2 affect the induction by activin signals of
Gain- and loss-of-function of activin-like signaling inhibit the sprouting of ISV Figure 4
Gain- and loss-of-function of activin-like signaling inhibit the sprouting of ISV. One blastomere of two-cell stage 
embryos was injected with constitutively active activin receptor (CA hALK4) DNA, dominant negative activin receptor (DN 
hALK4) DNA or dominant negative Smad3 (DN Smad3) DNA together with nuclear β-galactosidase mRNA as a lineage tracer 
and later subjected to insitu hybridization using Xmsr probe. (A) Uninjected control embryo. (B) CA hALK4 (1 ng)-injected 
embryo. (C) DN hALK4 (1 ng)-injected embryo. (D) DN Smad3 (1 ng)-injected embryo. (E) The graph showing the effects of 
CA hALK4, DN hALK4, DN Smad3 and DN Smad2 on the ISV sprouts.
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VEGF and MA genes, but not that of other early and late
target genes (Fig. 6). Given the expression of XDab2 in the
somites and vascular structures of early embryo, this indi-
cates that Dab2-mediated activin-like signaling may be
involved in somite tissue specification as well as angio-
genesis. However, since activin-like signaling could affect
the late mesoderm specification in the somites that is crit-
ical for blood vessel formation, we cannot exclude the
possibility that it could have indirect effects on vascular
development. Nevertheless, it is worth noting that activin-
like signaling employs specific mediators such as Dab2
only for the late specific developmental events but not for
the early ones in Xenopus embryos. In line with this, the
gain- and loss-of-function of XDab2 had no effects on the
axis formation and patterning of early embryos that are
regulated by Wnt and activin-like signaling pathway (data
not shown), though it is also known as an inhibitor of
Wnt signaling [33], indicating its specific function in late
XDab2 mediates the induction of VEGF by activin-like signaling Figure 5
XDab2 mediates the induction of VEGF by activin-like signaling. (A) RT-PCR analysis revealing that XDab2 MO (40 
ng), but not Co MO, inhibits the induction of VEGF gene by CA hALK4 RNA (2 ng) in animal cap tissues. +RT and -RT; control 
RT-PCR on the whole embryo RNA in the presence or absence of reverse transcriptase. AC, uninjected animal cap cells. Four-
cell stage embryos were injected into the animal pole region with a combination of the indicated reagents, and then animal caps 
isolated at late blastula stages were cultured to stage 20 and subsequently subjected to RT-PCR analysis. (B-E) VEGF gene 
expression could be reduced by Dab2 depletion but not by its overexpression. (D) XDab2 RNA (2 ng)-injected embryo. (E) 
hDab2 RNA (2 ng)-injected embryo. (F) The inhibition of activin-like signaling by injection of DN hALK4 (1 ng) decreased VEGF 
gene expression. (G) The table summarizing the results of Fig. 5B-F. (H-J) The angiogenic defects caused by XDab2 knockdown 
can be rescued by coexpression of VEGF. Arrows and arrowheads indicate the normal and inhibited ISV, respectively. The 
amount of injected reagents: 30 ng, Co Mo; 30 ng, XDab2 MO; 1 ng, VEGF mRNA. (K) The graph showing the results of Fig. 
5H-J.
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mesoderm specification and angiogenesis as shown our
data in Xenopus development. Although it is known that
other adaptor proteins such as SARA [52], Dok-1 [53],
Axin [54], the ELF β-spectrin [55] and cPML [56] are
involved in TGFβ signaling pathway, it remains to be fur-
ther investigated whether these adaptors also function in
angiogenesis or other specific events regulated by TGFβ
signaling in whole organisms.
Functional conservation of Dab2 in blood vessel 
development
During mouse embryogenesis, mouse Dab2  (mDab2)
expression is first observed in the primitive endoderm at
E4.5 and it is still restricted to the visceral endoderm at
E7.5 [29,30]. The homozygous Dab2-deficient mutant is
embryonic lethal (earlier than E6.5) due to the defective
visceral endoderm formation [29]. The conditional null
mice for Dab2 show defects in kidney function such as
reduction of transport by megalin, a lipoprotein receptor,
in the proximal tubule, but the kidney appeared grossly
normal, despite the absence of Dab2 protein that is nor-
mally expressed in the kidney proximal tubule cells [30].
Dab2 is also highly expressed in a variety of adult tissues,
including the kidney, ovary, liver, mammary gland, intes-
tine, uterus and heart [57]. Dab2 conditionally null mice
also appeared normal when Dab2-expressing organs such
as kidney, intestine and brain were analyzed [30]. How-
ever, there is no report that mDab2 is involved in angio-
XDab2 acts as a specific mediator of activin-like signaling for VEGF gene induction Figure 6
XDab2 acts as a specific mediator of activin-like signaling for VEGF gene induction. (A and B) Depletion of XDab2 
inhibits the induction by activin-like signal of late mesodermal target genes such as VEGF and muscle actin (MA) without affect-
ing that of early mesodermal (Chordin, Xbra and Mix2) and late endodermal (Sox17 and Endodermin) target genes in animal caps. 
(C) XDab2 enhances the activity of activin protein to induce VEGF, but the expression of other target genes was not changed 
by XDab2 overexpression. (A-C) Four-cell stage embryos were injected into the animal pole region with a combination of the 
indicated reagents and the animal caps isolated at stage 8 were cultured to stage 10.5 (B) or 20 (A and C) and then subjected 
to RT-PCR analysis. The amount of the injected reagents: 2 ng, CA hALK4 RNA; 40 ng, Co MO; 40 ng, XDab2 MO; 2 ng, 
XDab2 RNA. In panel (C), the animal caps were cultured in the presence of 5 ng/ml of activin protein. +RT and -RT; control 
RT-PCR on the whole embryo RNA in the presence or absence of reverse transcriptase. AC, uninjected animal cap cells.
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genesis during mouse embryogenesis yet. Although these
embryonic roles of mDab2 in mouse embryogenesis seem
to differ from those of XDab2 in many respects, we think
that the function of mDab2 in angiogenesis needs to be
investigated in the future research. On the other hand, a
recent study reported that zebrafish Dab2  (zDab2) is
expressed in caudal vein (CV) and dorsal aorta (DA) [58],
indicating its possible roles in blood vessel development.
Furthermore, we showed that the angiogenic defects by
XDab2 knockdown could be rescued by either human or
mouse  Dab2  genes (Fig. 3E and Additional file 3).
Together, these results suggest that the angiogenic func-
tion of Dab2 may be conserved during vertebrate develop-
ment.
Dab2 has two splicing variants including long (p96) and
short (p67) forms in mammals. Compared with the long
variant in mice, the short one lacks the exon 8 containing
two DPF and two of five NPF motifs which are implicated
in endocytosis. While p96 isoform is essential for normal
endocytosis and mouse development, expression of p67
alone led to decreased endocytosis and delayed develop-
ment [59], suggesting their distinct functions. Neverthe-
less, our study reveals that both of splicing isoforms have
similar functions in blood vessel development.
Supporting this, both of long and short splicing isoforms
of Dab2 disrupted similarly the sprouting of intersomitic
veins when overexpressed. Moreover, the angiogenic
defects caused by XDab2 depletion could be recovered by
coinjection of either. Thus, it is tempting to speculate that
the motifs critical for endocytosis which the long splicing
isoform has might be dispensable for blood vessel forma-
tion. Possibly, Dab2 could function as a signaling media-
tor but not as an adaptor for endocytosis in the angiogenic
events. On the other hand, it is possible that overexpres-
sion of short splicing isoforms such as XDab2 can inhibit
the ISV formation by competing off the long isoforms
which might be more relevant to blood vessel formation.
However, given that overexpression of XDab2  cannot
reduce VEGF expression that is critical for angiogenesis
(Fig. 5), its inhibitory effects on the ISV formation might
not be due to the impediment of the long isoform's func-
tion. Like XDab2, zebrafish Dab2 expressed in blood ves-
sels is more similar to short isoforms than long ones
(Tab.1). Probably, in lower vertebrates such as fish and
frog, a short isoform of Dab2 alone may play the same
roles that its two isoforms have in human and mice dur-
ing blood vessel development. In the future, it will be nec-
essary to elucidate the molecular mechanism by which
Dab2 regulates VEGF expression in activin-like signaling
pathways.
Conclusion
In summary, our study shows that Dab2 has a pivotal role
in embryonic angiogenesis during Xenopus early develop-
ment. In this process, it functions as a specific mediator of
VEGF  induction by activin-like signaling pathway. The
detailed mechanism governing the function of Dab2 in
vasculature, its significance in pathological angiogenesis,
and its functional conservation in other vertebrate devel-
opment remain to be elucidated.
Methods
Xenopus embryos and microinjection
Xenopus laevis was purchased from Xenopus I (Ann Arbor,
MI). Eggs were obtained from Xenopus laevis primed with
800 units of human chorionic gonadotropin (Sigma). In
vitro fertilization was performed as described previously
[60], and developmental stages of the embryos were deter-
mined according to Nieuwkoop and Faber [61]. Microin-
jection was carried out in 0.33 × Modified Ringer (MR)
containing 4% Ficoll-400 (Sigma) using a Nanoliter Injec-
tor (WPI). Injected embryos were cultured in 0.33 × MR
until stage 8 and then transferred to 0.1 × MR until they
had reached the appropriate stage for the experimentation
outlined below.
Plasmids, RNA synthesis, and morpholino oligonucleotides
For expression in Xenopus  embryos, the entire coding
region of XDab2 was cloned into the ClaI and XbaI sites of
the pCS2+ vector and into the ClaI site of the Myc-pCS2+
vector. Capped mRNAs were synthesized from linearized
plasmids using the mMessagae mMachine kit (Ambion).
XDab2  and  XDab2-Myc were linearized with NotI, and
mRNA was synthesized using SP6 RNA polymerase. Anti-
sense morpholino oligonucleotides (MO) were obtained
from Gene Tools. The morpholino oligonucleotide
sequences were as follows: XDab2 MO1, 5'-CTACATCAG-
TAGACATGACTGGAGG-3';  XDab2  MO2, 5'-CACAAT-
CATTAAATAAGAG TCAGAT-3'; control MO, 5'-
CCTCTTACCTCAGTTACAATTTATA-3'. DN hALK4  and
CA hALK4 in the pCS2+ vector were linearized with NotI.
DN Smad2 in the pSP64T vector was linearized with XbaI.
pCS2-DN  Smad3, pCS2-mDab2 (p96), pCS2-mDab2
(p67), pCS2-hDab2 and pCS2-xVEGF were generated by
subcloning of the coding regions of pRK5-DN Smad3,
pGEX-KG-mDab2 (p96), pGEX-KG-mDab2 (p67), pBSK-
xVEGF and pRK5-hDab2. These were linearized with NotI
for in vitro RNA synthesis.
In situ hybridization and sectioning of embryos
Whole-mount in situ hybridization was performed with
digoxigenin (DIG)-labeled probes as described by Har-
land [62]. Anti-sense insitu probes against XDab2  and
Xmsr were generated by linearizing the pBSKII-XDab2 con-
struct with BamHI  and pGEM7zf-Xmsr  construct with
EcoRI, respectively and transcribing with SP6 RNABMC Developmental Biology 2006, 6:63 http://www.biomedcentral.com/1471-213X/6/63
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polymerase. EphB4 and VEGF RNA probes are described
in [24,37].
For sectioning, embryos were fixed in MEMFA and then
rinsed three times in phosphate-buffered saline (PBS) and
soaked for 1 hour in 0.4% sucrose in PBS. Subsequently,
the embryos were washed in PBS and embedded in 4%
low-melting temperature agarose (Sigma). Embedded
embryos were sectioned per 50 μm on a Vibratome Series
1000 Plus (Vibratome).
Microangiography
We anesthetized stage 42 tadpoles in 0.02% ethyl 3-ami-
nobenzoate methanesulfonate (MS222, Sigma) dissolved
in 0.1× MR, placed them onto the agarose coated dish and
injected FITC-dextran (Sigma) into their hearts using glass
needles placed on a micromanipulator. We used fluores-
cent microscopy (Axiovert 200 M, Carl Zeiss) for imaging.
RT-PCR
Total RNA was prepared from embryos or animal cap
explants with TRI reagent (Sigma) and treated with
RNase-free DNase I (Roche) to remove genomic DNA.
RNA was transcribed by using M-MLV reverse tran-
scriptase (Promega). PCR amplification was performed
using Taq polymerase (TaKaRa). Primers and amplifica-
tion cycles for RT-PCR analysis were as follows:
XDab2  forward, 5'-CACTGGAAGCCTTGGCACCT-3';
XDab2  reverse, 5'-CCTTGTTGC GGCCAAACATT-3' (25
cycles); VEGF forward, 5'-TACATCCCCCATGCCCAGTT-
3'; VEGF reverse, 5'-TCTCATCAGGG GCACACAGG-3' (25
cycles); Primers for ODC, Sox17, Edd, MA, Xbra, Chordin
and Mix2 were as described in Dr. De Robertis' homepage
[63].
Western blotting analysis
For Western Blot analysis to test XDab2 MO specificity,
5'UTR and ORF XDab2-Myc mRNA were injected with
XDab2 MO1, MO2 or control MO into the animal region
of embryos at the four-cell stage and then the embryos
cultured until early neurula stage were homogenized in
Triton X-100 lysis buffer (20 mM Tris, 1% Triton X-100,
140 mM NaCl, 10% glycerol, 1 mM EGTA, 1.5 mM
MgCl2, 1 mM DTT, 1 mM sodium vanadate, 50 mM NaF,
10 μg/ml aprotinin, 10 μg/ml leupeptin). Equal amounts
of protein were separated by 10% SDS-PAGE. Western
blots were performed according to standard protocol with
anti-Myc (1:1000, Santa Cruz) and anti-actin (1:1000,
Santa Cruz) antibodies. Actin served as a specificity con-
trol.
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Additional material
Additional file 1
Gain-of-function of hDab2 impedes the sprouting of ISV in Xenopus 
embryo. (A) Injection of hDab2 RNA (2 ng) inhibited the formation of 
the sprouting ISV on the injected side of the embryo, and that on the unin-
jected side was normal. One blastomere of two-cell stage embryos was 
injected with hDab2 RNA along with β-gal RNA as a lineage tracer. 
Embryos were fixed at stage 34, stained for β-gal and then hybridized 
against Xmsr or EphB4. Arrowheads indicate disrupted ISV on the 
injected side of the embryo. Rectangular areas in the upper panels are 
enlarged in the lower panels. (B) The table summarizing the results from 
the gain-of-function analysis of hDab2.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1471-
213X-6-63-S1.pdf]
Additional file 2
The efficacy and targeting specificity of XDab2 MO. (A) The diagram 
indicating MO targeting site. (B) XDab2 MO inhibits specifically the 
translation of its cognate mRNA, but Co MO cannot. C-terminally Myc-
tagged XDab2 mRNA (1 ng) with or without MO targeting site was coin-
jected with Co MO (40 ng), MO1 (40 ng) or MO2 (40 ng) into the four-
cell stage embryos, and then embryos sampled at the early gastrula stages 
were subjected to western blotting analysis. Actin serves as a loading con-
trol. 5'UTR, XDab2-Myc mRNA with MO targeting site; ORF, XDab2-
Myc mRNA without MO targeting site.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1471-
213X-6-63-S2.pdf]
Additional file 3
Splicing isoforms of mDab2 have similar effects on the ISV formation 
in Xenopus embryo. (A) Injection of Co MO (30 ng) caused no defects 
in the sprouting ISV. (B-D) XDab2 knockdown inhibited the formation 
of ISV (B) and this angiogenic defect could be rescued by coexpression of 
mDab2 p67 (C) or mDab2 p96 (D) RNA. One blastomere of two-cell 
stage embryos was injected with XDab2 MO (30 ng) with or without 
mDab2 p67 or p96 RNA (250 pg), and then embryos fixed at stage 34 
were in situhybridized against Xmsr. Arrows and arrowheads represent 
the normal and disrupted ISV, respectively. (E) The table showing the 
results of Figure S3A-D. (F-I) Gain-of-function of mDab2 p67 or p96 
also disrupts the sprouting of ISV in Xenopus embryo. Injection of 
mDab2 p67 (F and G) or p96 (H and I) RNA (2 ng) inhibits the for-
mation of the sprouting ISV on the injected side of the embryo, with that 
on the uninjected side being normal. One blastomere of two-cell stage 
embryos was injected with β-gal RNA as a lineage tracer with mDab2 
p67 or p96 RNA. Embryos were fixed at stage 34, stained for β-gal and 
then hybridized against Xmsr (F and H) or EphB4 (G and I). Arrows 
and Arrowheads indicate normal and disrupted ISV on the injected side 
of the embryo, respectively. (J) The table showing the results of Figure 
S3F-I.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1471-
213X-6-63-S3.pdf]BMC Developmental Biology 2006, 6:63 http://www.biomedcentral.com/1471-213X/6/63
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